Access to quality, affordable, and timely health products is fundamental to achieving Universal Health Coverage (UHC). Yet across many low- and middle-income countries (LMICs), pharmaceutical systems remain vulnerable to regulatory fragmentation, import dependency, supply chain disruptions and limited local manufacturing capacity – weaknesses that became even more visible during the COVID-19 pandemic and subsequent global supply disruption.